Preliminary DCR of 61% reported in evaluable Ph 2 advanced breast cancer patients treated with Bria-IMT
“We are extremely pleased to report clinical benefit with our regimen in a heavily pre-treated patient who had failed prior ADC treatment,” commented Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “In addition to the longer than expected progression free and overall survival, we note the absence of serious complications such as potentially fatal interstitial lung disease (ILD) commonly associated with follow-on ADC treatments. The data supports the Bria-IMT™ approach as a promising therapeutic alternative to chemotherapy in advanced metastatic breast cancer.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data